Risk Test

Molecular diagnostics company Agendia today launched its ColoPrint test to predict risk of colon cancer recurrence. The microarray-based test looks at the expression of 18 genes associated with colon cancer recurrence and metastasis, says a release from the company. "ColoPrint's definitive results (either high or low risk with no in between) will enable doctors to choose treatment plans for colon cancer patients that are customized for each patient's individual needs," says Agendia's CEO David Macdonald in a statement. The company also offers MammaPrint, a test that predicts risk of breast cancer recurrence.